“Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patierns with type 2 diabetes, hypertension, and renal disease in Switzerland”, Swiss Med Wkly, vol. 136, no. 2122, pp. 346–346, May 2006, doi: 10.57187/smw.2006.11337.